NEW YORK, NY / ACCESS Newswire / August 27, 2025 / If you suffered a loss on your Biohaven Ltd. (NYSE:BHVN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biohaven-ltd-lawsuit-submission-form?prid=163860&wire=1&utm_campaign=26 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call […]

NEW YORK, NY / ACCESS Newswire / August 27, 2025 / If you suffered a loss on your Alto Neuroscience, Inc. (NYSE:ANRO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/alto-neuroscience-inc-lawsuit-submission-form?prid=163861&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / August 27, 2025 / If you suffered a loss on your Centene Corporation (NYSE:CNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/centene-corporation-lawsuit-submission-form?prid=163845&wire=1&utm_campaign=6 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 9:10 a.m. ET. https://mma.prnewswire.com/media/2543351/ADC_Therapeutics_SA__logo.jpg A webcast of the presentation

(NasdaqGM:LPAA), HAIFA, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that it has been chosen to receive a $350,000 grant from Countdown for a Cure for a research proposal related to the development

(NasdaqGM:LPAA), HAIFA, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that it has been chosen to receive a $350,000 grant from Countdown for a Cure for a research proposal related to the development

Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers GlobeNewswire August 27, 2025 HAIFA, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that it has been

Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers GlobeNewswire August 27, 2025 HAIFA, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that it has been

— One in five (21%) organizations have experienced an increase in safety incidents as a result of a poor hire — 73% say they feel under pressure to hire quickly, resulting in rushed recruitment decisions — Hirers increasingly demanding transferable skills such as attention to detail, problem-solving and communication, as well as technical skills —

NEW YORK, NY / ACCESS Newswire / August 27, 2025 / If you suffered a loss on your RxSight, Inc. (NASDAQ:RXST) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rxsight-inc-lawsuit-submission-form?prid=163843&wire=1&utm_campaign=17 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call